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Abstract
Detection of adverse drug reactions (ADRs) in hospitals provides an important measure 
of the burden of drug related morbidity on the healthcare system. Spontaneous reporting of 
ADRs is scare and several obstacles to such reporting have been identified formerly. This study 
aimed to determine the role of clinical pharmacy residents in ADR reporting within a hospital 
setting.Clinical pharmacy residents were trained to report all suspected ADRs through ADR-
reporting yellow cards. The incidence, pattern, seriousness, and preventability of the reported 
ADRs were analyzed. During the period of 12 months, for 8559 patients, 202 ADR reports were 
received. The most frequently reported reactions were due to anti-infective agents (38.38%). 
Rifampin accounted for the highest number of the reported ADRs among anti-infective agents. 
The gastro-intestinal system was the most frequently affected system (21.56%) of all reactions. 
Fifty four of the ADRs were reported as serious reactions. Eighteen of the ADRs were classified 
as preventable. Clinical pharmacy residents involvement in the ADR reporting program could 
improve the ADR reporting system. 
Keywords: Adverse drug reaction; Clinical pharmacist; Pharmacy resident; Hospital, 
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prospectively and retrospectively collecting data 
on suspected ADRs. Prospective ADRs were 
identified by physicians, nurses, or residents 
during interdisciplinary rounds. Retrospective 
ADRs were identified by reviewing patient’s 
records. The residents documented the 
suspected drug(s) for the event on yellow cards. 
Pharmaceutical care department staffs reviewed 
each ADR report and were responsible for the 
accuracy of the reported ADR. 
An ADR was defined according to the 
World Health Organization (WHO) definition 
as: “a response to a drug which is noxious and 
unintended, and which occurs at doses normally 
used in man for the prophylaxis, diagnosis, or 
therapy of disease, or for the modification of 
physiological function.”
Each ADR was classified according to 
the WHO system organ classification (9). All 
reported ADRs were evaluated for the causality 
in accordance with Naranjo’s algorithm (10). 
The seriousness of reported adverse reactions 
was assessed based on the WHO definition, 
which included any adverse event that resulted in 
death, life-threatening situation, hospitalization, 
prolonged hospital stay, disability or birth defect. 
Assessment of preventability was determined 
using the scale developed by Schumock et al.(11).
All documented ADRs were electronically 
entered into an Excel spreadsheet for the purpose 
of generating annually reports. ADR forms were 
then sent to the national ADR monitoring centre 
at the Ministry of Health for further evaluation.
The number and reporting rate (number of 
reports/number of beds) of ADRs were compared 
with our previous study (12).
Results
During 12 months, a total of 8559 patients 
were admitted to the hospital. Sixteen clinical 
pharmacy residents were rotating who reported 
202 ADRs from 178 patients. A total of 202 
ADRs were documented in this study, compared 
with 112 in previous study (12).
In terms of the patient demographics in the 
reported ADRs, 111 were women and 91 were 
men. 
Number of patients in pediatric (0–18 years), 
adult (19–60 years) and geriatric (> 60 years) 
Introduction
Adverse drug reactions (ADRs) are common 
causes of morbidity and mortality within the 
hospital setting. The hospital setting, with its 
clearly defined patient population, is an ideal 
setting to identify potential adverse drug reaction 
signals and to report them to either the drug 
company or the FDA (1). Reporting of ADRs 
is an important component of monitoring and 
evaluation activities performed in the hospitals. 
A productive hospital-based reporting program 
can be helpful in providing valuable information 
regarding potential problems of drug usage in 
an institution. Through these efforts, problems 
are identified and resolved, which results in 
continuous improvement in patient care (2).
Spontaneous reporting program, a common 
method of drug surveillance is capable of 
recognizing ADRs in the daily medical practice, 
even though underreporting and absence of 
information on ADRs are its disadvantages (3, 
4). Although identification and documentation 
of ADRs are considered as all health care 
professionals’ responsibility, pharmacists and 
especially clinical pharmacists are often in 
charge for these tasks (5). 
Clinical pharmacy is relatively a new concept 
in Iran (6). This new breed of pharmacy practices 
is more patient oriented rather than drug product 
oriented (7). Clinical pharmacy residents are in 
an ideal position to increase ADR reporting rates 
within health systems (8). ADR review can be 
added to the daily responsibilities of residents 
participating in the hospitals and clinical 
rotations. In this article we tried to demonstrate 
the contribution of clinical pharmacy residents 
in the process of ADR reporting within a 
hospital setting and assess the role of the clinical 
pharmacy residents on the number and reporting 
rate of ADRs.
Exprimental
The study was conducted in Masih Daneshvari 
Hospital over a one year period from March 2010 
to February 2011. During the orientation session 
at the beginning of each new rotation, residents 
received a brief overview of the hospital’s 
ADR reporting program. Residents began 
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groups were 11, 112 and 79, respectively. ADRs 
were reported from 8 wards. The majority of 
the ADR reports were from the Department of 
Internal Medicine (31.68%), followed by the 
Coronary Care Unit (16.83%) as presented in 
Table 1. The most frequent reports were due 
to anti-infective agents (38.38%), followed 
by antineoplastic agents (11.45%) and central 
nervous system agents (10.44%). The drug class 
involved in the ADRs is shown in Table 2.
Rifampin was the most frequent anti-infective 
agent associated with the suspected ADRs such 
as nausea, vomiting, abdominal pain, urticaria, 
hepatic enzyme increased, pancytopenia, and 
Stevens-Johnson syndrome (SJS) (Table 3).
The gastrointestinal system was the most 
frequently affected system (21.56% of all 
reactions), followed by the skin and appendages 
system (14.50%). The classification of the ADRs 
by system-organ class is demonstrated in Table 
4. The causality assessment of ADRs revealed 
that 35.64% as probable and 64.36% as possible 
reactions. Fifty four (26.73%) of the ADRs were 
classified as serious according to the WHO 
definition and resulted in prolonged hospital 
stay, persistent disability or death. Table 5 shows 
the drugs with a serious reaction. 
Eighteen (8.91%) of the ADRs were classified 
as preventable according to the scale developed 
by Schumock et al.(11).
Discussion
The contribution of clinical pharmacy 
residents in improving ADR reporting was 
determined by comparing current with 
previous ADR data. A total of 202 ADRs were 
documented in this study, compared with 112 
in previous study (12) an increase of almost 
twofold. Reporting rate of ADRs in our center 
was increased from 40% in year 2006 to 80% in 
year 2010.
Sullivan et al. showed that pharmacy student 
participation in the ADR reporting significantly 
increases the number of ADRs documented (5). 
Until recent years, colleges of pharmacy in 
Iran had no clinical education (13). Significant 
progress has been made since 1996 toward 
changing the emphasis of pharmaceutical 
Ward Number of ADRs Percentage
Internal medicine 64 31.68
Cardiac Care Unit 34 16.83
Intensive Care Unit 29 14.36
Tuberculosis 28 13.86
Oncology 26 12.87
Surgery 9 4.46
Pediatric 7 3.47
Transplant 5 2.48
Table 1. Wards associated with the reported ADRs. 
Drug class Number of ADRs Percentage
Anti-infective agents 114 38.38
Antineoplastic agents 34 11.45
Central nervous system agents 31 10.44
Cardiovascular drugs 24 8.08
Miscellaneous Therapeutic Agents 19 6.40
Blood formation and coagulation 17 5.72
Autonomic drugs 16 5.39
Hormones and synthetic substitutes 15 5.05
Electrolytic, Caloric, and Water Balance 11 3.70
Gastrointestinal drugs 9 3.03
Antitussives, Expectorants, and Mucolytic Agents 4 1.35
Antihistamine drugs 1 0.34
Vitamins 1 0.34
Eye, Ear, Nose, and Throat preparations 1 0.34
Table 2. Drug class implicated in the reported ADRs.
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Anti-infective agents Number of ADRs Percentage
Rifampin 23 20.35
Isoniazid 21 18.58
Pyrazinamide 18 15.93
Vancomycin 14 12.39
Clindamycin 5 4.42
Ceftriaxone 4 3.54
Co-trimoxazole 4 3.54
Clarithromycin 4 3.54
Ofloxacin 4 3.54
Ethambutol 3 2.65
Azithromycin 2 1.77
Dapsone 1 0.88
Erythromycin 1 0.88
Oseltamivir 1 0.88
Ganciclovir 1 0.88
Chloramphenicol 1 0.88
Linezolid 1 0.88
Nitrofurantoin 1 0.88
Penicillin 1 0.88
Cefalexin 1 0.88
Meropenem 1 0.88
Piperacillin 1 0.88
Table 3. Anti-infective agents implicated in ADRs. 
System associated with ADRs Number of ADRs Percentage
Gastro-intestinal system 58 21.56
Skin and appendages 39 14.50
Central & peripheral nervous 
system 31 11.52
Metabolic and nutritional 22 8.18
Liver and biliary system 20 7.43
Platelet, bleeding & clotting 18 6.69
Respiratory system 13 4.83
Vascular (extracardiac) 12 4.46
Body as a whole-general 10 3.72
Psychiatric 10 3.72
Vision 6 2.23
Red blood cell 5 1.86
Urinary system 4 1.49
White cell 4 1.49
Musculo- skeletal system 4 1.49
Cardiovascular 3 1.12
Resistance mechanism 3 1.12
Heart rate and rhythm 2 0.74
Application site 2 0.74
Special senses other 2 0.74
Hearing and vestibular 1 0.37
Table 4. Organ systems associated with the reported ADRs.
education from preparing a product-oriented 
pharmacist to preparing a patient- oriented 
individual with good basic knowledge of drugs. 
These pharmacists can work in close association 
with physicians and others on the health care 
teams (14). It is the pharmacist’s responsibility 
and professional commitment to report any 
suspected ADRs (15).
In our study, the most frequent ADRs were 
related to antibiotics that are costy and highly 
consumed in our hospital. While in other studies, 
different drug classes such as antineoplastic, 
cardiovascular, anticoagulant, nonsteroidal anti-
inflammatory, hypoglycemic, and anti-infective 
agents have been most frequently associated 
with ADRs (16-21).
Our previous study has shown ceftriaxone as 
the most frequent anti-infective agent associated 
with the suspected ADRs (12). Perhaps emphasis 
on the appropriate and rational use of this drug 
by pharmaceutical care department in the rounds, 
consultations, random medication reviews, or via 
newsletter, (22-25), has changed drug utilization 
pattern and consequently ADR pattern. 
In the present study rifampin has been 
replaced as the most frequent anti-infective agent 
associated with the suspected ADRs. It could 
be rational since our hospital is a tuberculosis 
referral center and therefore rifampin is highly 
prescribed. 
Gastro-intestinal system was the most 
reported organ system which was affected by 
ADRs. Skin and appendages systems have 
usually been reported as the most affected 
organ system by ADRs (26-28). This reveals 
that clinical pharmacy residents have used their 
clinical judgments which could be superior 
to documenting only those visible ADRs. 
Pathological and laboratory data which are 
objective markers of ADRs should be considered 
by residents (12).
In this study, 8.91% of ADRs were 
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Drugs Type of reaction Number of reports
Rifampin
Hepatic enzyme increased 9
Pancytopenia 1
Stevens Johnson Syndrome 1
Isoniazid Hepatic enzyme increased 8
Heparin
Thrombocytopenia 3
Haematuria, Gastric ulcer hemorrhagic, 
Ecchymosis 1
Cyclosporine
Nephropathy toxic, Hepatic enzyme increased 2
Vomiting, Nausea 1
Vancomycin
Renal failure 1
Thrombocytopenia 1
Carboplatin
Pancytopenia 1
Leucopenia, Anemia 1
Anti-thymocyte globulin Thrombocytopenia 2
Insulin Regular Hypoglycemia 2
Mycophenolate mofetil Leucopenia,  Neutropenia 2
Ranitidine Thrombocytopenia 1
Allopurinol Stevens Johnson Syndrome 1
Amiodarone Thrombocytopenia, Anemia 1
Betaxolol Dyspnoea, Bronchospasm 1
Carbamazepine Dyspnoea, Dermatitis 1
Co-trimoxazole Anemia 1
Digoxin Thrombocytopenia 1
Cyclophosphamide Pulmonary edema, Oedema peripheral 1
Enoxaparin Thrombocytopenia 1
Hyoscine Dyspnoea 1
Insulin NPH Hypoglycemia 1
Morphine sulfate Convulsion 1
Propranolol Bronchospasm, Dyspnoea, Consciousness decreased 1
Pyrazinamide BUN increased 1
Sodium valproate Thrombocytopenia 1
Warfarin Pulmonary haemorrhage 1
Ceftriaxone Allergic reaction 1
Table 5. Drugs reported in serious ADRs by frequency of times reported and type of reaction.
preventable. Higher rate of preventable ADRs 
in other studies (the wide range of 30-70%) (28, 
29) and 13.39% reduction in preventable ADRs 
in our hospital (22.30% preventable ADRs in 
previous study) suggest that preventive strategies 
have been effective in our institute.
Serious ADRs have been increased from 
16.70% (in previous study) to 26.73% (in this 
study). Perhaps clinical pharmacy residents are 
eligible to detect serious ADRs more efficiently. 
The assessment of whether an ADR has increased 
the length of stay or caused persistent disability 
or death can be difficult to assess because 
individual patient factors such as the nature and 
severity of the underlying disease, and social 
factors may also contributed to the length of stay 
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